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Table. Clinical outcomes at 5-Year
Endpoints
TA group(N¼2120)
non-TA
group(N¼1205) Crude
p
Adjusted
p
N of events
(Cumulative
incidence)
N of events
(Cumulative
incidence)
HR
(95％CI)
HR
(95％CI)
All-cause death 375(18.6％) 265(22.9％) 0.78(0.67-0.90) <0.001 0.91(0.77-1.09) 0.30
Cardiac death 230(11.3％) 230(11.3％) 0.82(0.68-1.00) 0.049 1.00(0.79-1.26) 0.99
Non-cardiac
death
145(8.2％) 103(10.4％) 0.71(0.56-0.90) 0.005 0.79(0.61-1.03) 0.09
MI 110(5.9％) 71(6.9％) 1.00(0.93-1.08) 0.32 0.89(0.65-1.22) 0.47
Stroke 100(5.4％) 70(6.9％) 0.75(0.56-1.00) 0.052 0.78(0.56-1.09) 0.15
Stent
thrombosis
51(2.7％) 30(2.8％) 0.95(0.62-1.49) 0.82 0.89(0.56-1.42) 0.61
TLR 423(22.2％) 272(25.6％) 0.85(0.73-0.99) 0.033 0.93(0.78-1.10) 0.40
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMSTEMI randomly assigned to thrombus aspiration or conventional primary PCI group
before coronary angiography. The primary endpoint was deﬁned as a signiﬁcant reduction
of IMR in thrombus aspiration compared to conventional PCI group.Myocardial perfusion
grade and resolution of ST-segment elevation were also assessed. Infarct size and left
ventricle remodeling were assessed by echocardiographic indices and SPECT.
Results: Manual thrombus aspiration, as compared with conventional PCI, resulted in
signiﬁcantly lower IMR (31.921.3 U vs. 47.035.8 U, P ¼ 0.0082). Treatment with
thrombus aspiration, as compared with conventional PCI, resulted in similar rates of
myocardial perfusion grade 0 or 1 (20.8% vs. 29.4%; relative risk, 0.71; 95% CI, 0.38
to 1.30; P¼0.26) and complete resolution of ST-segment elevation (59.7% vs. 47.1%;
relative risk, 1.27; 95% CI, 0.90 to 1.79, P¼0.17). In a multiple regression model with
the log-transformed IMR as dependent variable, after adjusting for clinical, angio-
graphic and procedural variables, thrombus aspiration remained a strong independent
predictor of lower IMR (27.14 U; 95% CI, 23.79 to 30.95 U, vs. 36.11 U; 95% CI,
30.74 to 42.41 U, P¼0.0076). Histopathological examination conﬁrmed successful
thrombus aspiration in 89.6% of patients.
Conclusions: Manual thrombus aspiration reduces microcirculatory resistance indi-
cating better myocardial perfusion compared to conventional PCI in patients with
STEMI. Manual thrombus aspiration tended towards improved clinical outcome.
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Thrombus aspiration is similarly effective in STEMI patients with ischemia
lasting less than 6 hours compared to those with longer ischemia: subanalysis of
the PATA STEMI trial
Dejan Orlic1, Dejan Milasinovic1, Milorad Zivkovic1, Milorad Tesic1,
Vladimir Dedovic1, Zlatko Mehmedbegovic1, Branko Beleslin1, Miodrag C. Ostojic2
1Clinical Center of Serbia, Belgrade, Serbia, 2Medical School University of Belgrade,
University City Hospital “Zvezdara” Belgrade, Belgrade, Serbia and Montenegro
Background: It has been reported that thrombus aspiration is effective in STEMI
patients with total ischemic time duration of less than 3 hours and less effective in
longer ischemia. Some studies tested thrombus aspiration efﬁcacy only within 6 hours
from chest pain onset. However, little is known about invasive assessment of
thrombus aspiration efﬁcacy in STEMI patients beyond 6 hours of ischemia.
Methods: Patients who underwent thrombus aspiration were divided into two groups
according to total ischemic time duration:< 6 hours and6 hours. These patients were
taken from the PATA STEMI trial for the analysis. Primary endpoint was value of mean
index of microcirculatory resistance (IMR). Secondary endpoints were myocardial
blush grade (MBG), resolution of ST segment elevation, AUC CK, wall motion score
index (WMSI), left ventricular ejection fraction and MACE rate at one year follow-up.
Results: In the PATA STEMI trial 75 patients underwent manual thrombus aspiration
with the Eliminate3 catheter (Terumo Europe, Leiden, Belgium). In baseline charac-
teristics, patients delay (74,5 vs 377,9, P¼0,00018) and multivessel disease (46,0% vs
83,3%, P¼0,026) were more frequent in patients with total ischemic time 6 hours
(N¼12). In patients with totals ischemic time< 6 hours (N¼63) compared to those with
6 hours, mean IMR was 30,417,8 vs. 36,419,8 U, P¼0,34 (mean corrected IMR
26,515,8 vs. 34,319,9 U, P¼0,22), mean IMR in non-infarct related artery teritory
18,68,0 vs 24,24,0 U, P¼0,21, complete resolution of ST-segment elevation 63,5%
vs. 50%, P¼0,53, myocardial blush grade 2 in 80,9% vs. 66,7%, P¼0,44, AUC CK
4030325380 vs. 4443130316 U/L, P¼0,69, WMSI 1,320,33 vs. 1,180,19,
P¼0,06, LVEF 53,9% vs. 59,3%, P¼0,11 and MACE rate 11,1% vs. 0%, P¼0,59.
Conclusions: Manual thrombus aspiration in STEMI patients with ischemia lasting
less than 6 hours is similarly effective as in those with longer ischemia.
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Impact of manual thrombus aspiration on left ventricular remodeling: the
echocardiographic substudy of the randomized Physiologic Assessment of
Thrombus Aspiration in patients with ST-segment Elevation Myocardial
Infarction (PATA STEMI) trial
Dejan Orlic1, Milorad Tesic1, Danijela Trifunovic1, Bosiljka Vujisic1,
Branko Beleslin1, Miodrag C. Ostojic2
1Clinical Center of Serbia, Belgrade, Serbia, 2Medical School University of Belgrade,
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Background: It has been reported that index of microcirculatory resistance (IMR) is
lower in STEMI patients who underwent thrombus aspiration before stent implantation
compared to those tretaed with conventional primary PCI. The aim of this study was to
evaluate impact of improved myocardial perfusion by manual thrombus aspiration
assessed by IMR on left ventricular remodeling in STEMI patients at mid-term follow-up.
Methods: The total of 115 patients entered the echocardiography substudy of the
PATA STEMI (randomized Physiologic Assessment of Thrombus Aspirtion in pa-
tients with ST-segment Elevation Myocardial Infarction) trial which evaluated eﬁcacy
of manual thrombus aspiration using Eliminate3 catheter (Terumo Europe, Leuven,
Belgium). Echocardiography was done within the ﬁrst 24 hours after the index pro-
cedure and after 4 months. End-diastolic and end-systolic left ventricular (LV) vol-
umes, ejection fraction (EF), cardiac sphericity index (CSI) and regional wall motion
score index (WMSI) were calculated.
Results: In baseline characteristics, in patients with thrombus aspiration compared to
those with conventional primary PCI, total ischemic time tended to be longer
246,7181,8 vs. 200,9110,1min, P¼0,09 andAUCCKwas smaller 4009026158U/L
vs. 5267632013 U/L, P¼0,026. Also, corrected IMR was lower in thrombus aspirationJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Cagroup 27,516,8 vs. 39,932,7 U/L, p¼0,0079, while CFR (1,680,81 vs. 1,610,67,
P¼0,6) and mean capilary wedge pressure (20,46,6 vs. 21,47,8 mmHg, P¼0,5) were
similar. End-diastolic and end-systolic LV volumes per body surface area, EF, CSI volume
and WMSI were similar between the thrombus aspiration and no aspiration group at
baseline and at follow-up. At follow-up, percent change in WMSI tended to be greater in
thrombusaspirationgroup (decrease inWMSI8,2%vs. increase inWMSI0,8%,P¼0,094).
Conclusions: Improved myocardial perfusion assessed by IMR has no impact on left
ventricular remodeling in STEMI patients at mid-term follow-up.
TCT-144
The clinical efﬁcacy of thrombus aspiration on ﬁve-year clinical outcomes in
patients with ST-segment elevation acute myocardial infarction undergoing
percutaneous coronary intervention
HIroki Watanabe1, Hiroki Shiomi2, Takeshi Kimura2
1Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Kyoto University,
Kyoto, Japan
Background: The use of adjunctive thrombus aspiration (TA) promotes better cor-
onary reperfusion and improves myocardial perfusion in STEMI but the long-term
mortality beneﬁt still remains controversial.
Methods: The CREDO-Kyoto AMI registry is a large-scale cohort study of acute
myocardial infarction (AMI) patients undergoing coronary revascularization in 2005-
2007 at 26 hospitals in Japan. Among 5429 patients enrolled in the registry, the
current study population consisted of 3325 patients who arrived at the hospital within
12 hours after the symptom onset and underwent primary PCI. During primary PCI,
2120 out of 3325 (63.8%) patients received thrombus aspiration (the TA group).
Clinical outcomes were compared between the TA group and the non-TA group.
Results: The cumulativeﬁve-year incidence of all-cause deathwas signiﬁcantly lower in
the TA group than in the non-TA group (18.6% versus 22.6%, P< 0.001). Similarly, the
cumulative incidences of cardiac death, non-cardiac death, and target-lesion revascu-
larization (TLR) were signiﬁcantly lower in the TA group. After adjusting for
confounders, however, the use of adjunctive TA was not associated with lower risk for
all-cause death (hazard ratio [HR]:0.91, 95% conﬁdence interval [CI]:0.77-1.09,
P¼0.30). In contrast, the subgroup analysis indicated TAwas associated with a lower all-
causemortality only in patients with initial TIMI grade 1-3(HR: 0.70, 95%CI:0.52-0.94,
P¼0.02). Adjunctive thrombus aspiration had a neutral effect in the rest of the subgroups.Conclusions: Adjunctive thrombus aspiration was not associated with better ﬁve-year
mortality beneﬁt in STEMI patients who underwent primary PCI.Cath Lab of the Future
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RADIATION PROTECT: A randomized trial to assess the effectiveness of a
novel pelvic lead shield and a novel, non-lead surgical cap to reduce operator
radiation exposure during coronary angiography or intervention
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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comBackground: Radiation exposure is associated with increased risk of malignancies and
cataract formation. Recent case series of predominantly left sided brain malignancies in
interventional cardiologists suggest an increased risk with long term exposure to
occupational radiation. These data suggest that further measures to protect healthcare
workers are needed. We aimed to evaluate the efﬁcacy of two novel shields in reducing
interventional cardiologists’ radiation exposure during angiographic procedures.
Methods: We conducted a prospective, randomized, controlled clinical trial with
enrollment of 230 patients undergoing coronary angiography or percutaneous coronary
intervention from November 2013 to May 2014. Patients were randomized to have their
procedure performedwith orwithout placement of a pelvic lead shield designed for either
radial or femoral access, and designed to reduce radiation scatter. During all procedures,
an interventional cardiologist was ﬁtted with a novel, paper thin, non-lead surgical cap
(No Brainer, RADPAD, weight 53 grams) to protect the brain from radiation exposure.
The co-primary outcomes for the lead shield comparison was i) the difference between
both groups in total operator radiation dose (mSv) at the left chest level and ii) the dif-
ference between groups in operator dose divided by Air Kerma (mSv/mGy). For the cap
comparison, the primary outcome was the difference between total radiation dose (mSv)
as measured by two dosimeters at left temporal region of the head of the interventional
cardiologist (one on the outside of the cap and the other one on the inside of it). Radiation
dose was measured using Unfors Educational Direct Dosimeters (EDD-30).
Results: The full results of the study will be available at time of presentation.
Conclusions: The RADIATION PROTECT study will help determine the efﬁcacy of
a novel lead shield and a novel non-lead surgical cap for reducing operator radiation
exposure during coronary angiography or intervention.
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Patient And Occupational Dose Reduction Enabled By A Novel X-ray Imaging
Technology For Interventional Cardiology: First Results
Liesbeth Eloot1, Klaus Bacher1, Thomas Gijs1, Emma Vanhalst1
1Ghent University, Ghent, Belgium
Background: During interventional cardiology procedures patient and staff are
exposed to X-ray radiation. Minimizing radiation dose is a crucial part of quality care.
This study quantiﬁes the radiation dose reduction for patient and staff enabled by a
novel X-ray imaging technology using advanced real-time image noise reduction
algorithms and an optimized acquisition chain (AlluraClarity, Philips Healthcare, The
Netherlands). First results are reported.
Methods: Between March-May 2014, 48 patients referred for coronary angiography
and angioplasty were prospectively scheduled and randomized for room A (FD10
monoplane system with state of the art image processing and reference acquisition
chain) or room B (FD2010 biplane system with the novel imaging technology) in a
1:2 ratio. Patients’ demographics and procedure characteristics were recorded; expo-
sure parameters from all planes were logged via DICOM SR. Scatter dose is quantiﬁed
by a dosimeter placed on the C-arc, at a ﬁxed position, not affected by any shielding
device. Occupational dose is quantiﬁed by dosimeters placed on the torso and leg of
physicians and logged via DICOM SR (DoseAware Xtend, Philips Healthcare, Best,
The Netherlands).
Results: Demographic data, exposure parameters and occupational doses are sum-
marized in Table 1, showing comparable patient demographics and procedure
complexity for room A and B. DAP values for ﬂuoroscopy and exposure decreased
with 33% and 75%, respectively. Scatter dose decreased with 67% in room B for the
C-arc dosimeter and 53% for the physician leg. However, physician torso dose (less
than 35% of leg dose) did not differ signiﬁcantly. This needs to be further investigated.Table 1. Patient demographic data and exposure parameters
Room A (n¼17) Room B (n¼31) p-value
No. of males / females 15 / 2 16 / 15 0.11
Age, y 66 (58-78) 64 (59-69) 0.706
BMI, kg/m2 27 (24-31) 26 (23-31) 0.612
Only CA / CA+PCI 16 / 1 25 / 6 0.206
DAP total, Gycm2 64.7 (48.7-90.6) 20.4 (13.5-34.7) <0.001
DAP ﬂuoro, Gycm2 7.02 (3.56-11.2) 4.70 (3.02-14.3) 0.348
DAP exposure, Gycm2 56.5 (45.3-75.1) 14.2 (9.81-22.8) <0.001
No. of exposure images 858 (709-916) 1070 (767-1311) 0.013
No. of exposure runs 11 (10-12) 12 (10-13) 0.206
Fluoroscopy time, s 116 (74-195) 172 (114-301) 0.062
CMV, mL 112 (104-130) 119 (99-138) 0.746
Reference scatter dose, mSv 728 (506-875) 241 (118-426) <0.001
Physician leg dose, mSv 226 (137-343) 106 (51.0-151) 0.004
Physician torso dose, mSv 36.2 (13.4-129) 51.5 (26.0-74.6) 0.525
BMI: body mass index; DAP: dose area product; CMV: contrast medium volume. Values
represent the median (Q1-Q3).Conclusions: The novel X-ray imaging technology resulted in a signiﬁcant and
substantial patient and occupational dose reduction, without affecting patient and
procedure characteristics.B44 JACC Vol 64/11/Suppl BTCT-147
Patient radiation exposure with a novel X-ray imaging technology during
coronary angiography and angioplasty
Fernando Cura1, Bonvini Victor2, Pablo Lamelas3, Gustavo O. Pedernera4,
Pablo Spaletra5, Gerardo Nau1, Lucio T. Padilla3, Alfonsina Candiello6, Jorge Belardi2
1Instituto Cardiovascular de Buenos Aires, Buenos Aires, Buenos Aires, 2Instituto
Cardiovascular de Buenos Aires, Buenos Aires, Argentina, 3ICBA, Buenos Aires,
Argentina, 4ICBA, BsAs, BsAs, 5ICBA, Bs As, Bs As, 6ICBA, Buenos Aires, Buenos Aires
Background: A novel X-ray imaging technology (AlluraClarity, Philips Healthcare,
Best, The Netherlands) enables patient radiation dose reduction by a combination of
advanced image noise reduction algorithms with state-of-the-art hardware and an
anatomy-speciﬁc optimized full acquisition chain. The main purpose of this analysis is
to quantify patient radiation exposure during coronary angiography and intervention in
real life using the novel ClarityIQ technology.
Methods: Retrospective data was collected for the entire cohort of patients admitted
for coronary interventions with the Allura Xper or AlluraClarity in our institution
during the period November 2013 to March 2014. Patients were allocated to each
equipment according to availability, unrelated to patient’s characteristics and condi-
tions. The primary endpoint was overall procedural patient dose, expressed in air
kerma and dose area product (DAP).
Results: The analysis comprised 1215 consecutive patients undergoing coronary
diagnostic and therapeutic interventions, 532 (44 %) performed with AlluraClarity and
683 (56 %) with the Allura Xper. Clinical characteristics were similar among both
groups, including BMI and weight. Air Kerma in the Allura Xper and AlluraClarity
group were 930 mGy (IQR 517-1686) and 591 mGy (IQR 319-1173), respectively
(37% reduction with Clarity, 95%CI 32 to 42%; p < 0,0001). DAP in the Xper and
Clarity group were 98959 mGy/cm2 (IQR 52944-174757) and 59042 Gy/cm2 (IQR
32382.5-106784.5), respectively (41% reduction with Clarity, 95%CI 36 to 46%;
p < 0,0001). Same radiation exposure reduction with Kerma and DAP were detected
adjusting by radiation time. No signiﬁcant differences were detected on radiation time
(8.4 vs 9.2 minutes; p ¼ 0,58) or contrast used adjusted by radiation time (13,6 vs
13,20 mL/min; p ¼ 0,32) in the Xper and Clarity group, respectively.
Conclusions: A profound reduction in procedural patient radiation exposure was
measured by comparing the AlluraClarity with the Allura Xper equipment for patients
undergoing coronary interventions with no impact in the radiation time and contrast
use. Reduction of patient and operator radiation exposure is one of the most important
challenges of modern cathlabs.
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Feasibility of Complex Robotic Percutaneous Coronary Intervention
Arturo Dominguez1, Ryan Reeves1, John Bahadorani2, Mitul Patel3,
Ehtisham Mahmud4
1University of California, San Diego, San Diego, CA, 2UCSD, La Jolla, CA,
3University of California San Diego, La Jolla, CA, 4University of California,
San Diego, San Diego, United States
Background: The safety and feasibility of robotic-assisted percutaneous coronary
intervention (PCI) with the CorPath 200 (Corindus, Boston, MA) in simple coronary
lesions has been demonstrated.
Methods: This is a single center registry report of all consecutive robotic assisted PCI
procedures performed with the CorPath 200.
Results: We enrolled 19 patients (mean age 68;74% male) and demonstrate that 52%
of the cases performed were for type C lesions, with 16 of 19 cases performed entirely
robotically or with minimal manual manipulation. Procedural and clinical success for
the series and contrast/ﬂuoroscopy time used for the group are reported.
Conclusions: The CorPath 200 robotic system can be used to treat complex coronary
lesions including type C lesions, saphenous vein graft lesions, chronic total occlusions,
multilesion ormultivessel disease, andwith arterial access obtainedvia the radial approach.j September 13–17, 2014 j TCT Abstracts/Cath Lab of the Future
